Form 4 for MBX MBX Biosciences, Inc.
Accepted 2024-09-17 00:00:00 ET · period of report 2024-09-16 · accession 0000950170-24-107530 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-09-17 | 2024-09-16 | MBX | Heron Patrick J | Dir, 10% | P - Purchase | $16.00 | +625.0K | 4.55M | +16% | +$10.00M |
| DI | 2024-09-17 | 2024-09-16 | MBX | Heron Patrick J | Dir, 10% | C - Cnv Deriv | — | +3.93M | 3.93M | New | — |
| DMI | 2024-09-17 | 2024-09-16 | MBX | Heron Patrick J | Dir, 10% | C - Cnv Deriv | — | -47.22M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-16 | P | A | 625,000 | $16.00 | 4,552,774 | I By Frazier Life Sciences X, L.P. | — | — | (F3) Reflects shares purchased in the Issuer's initial public offering. (F2) These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| 2 | Common | Common Stock | 2024-09-16 | C | A | 3,927,774 | — | 3,927,774 | I By Frazier Life Sciences X, L.P. | — | — | (F1) Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. (F2) These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| 3 | Derivative | Series B Convertible Preferred Stock | 2024-09-16 | C | D | 28,297,265 | — | 0 | I By Frazier Life Sciences X, L.P. | — · — to — | 2,353,769 Common Stock | (F1) Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. (F2) These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| 4 | Derivative | Series A Convertible Preferred Stock | 2024-09-16 | C | D | 18,922,852 | — | 0 | I By Frazier Life Sciences X, L.P. | — · — to — | 1,574,005 Common Stock | (F1) Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. (F2) These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |